Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to -$7.6 million.

  • TransMedics' Cash from Investing Activities rose 8403.75% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.3 million, marking a year-over-year increase of 6359.52%. This contributed to the annual value of -$129.3 million for FY2024, which is 3333.28% up from last year.
  • According to the latest figures from Q3 2025, TransMedics' Cash from Investing Activities is -$7.6 million, which was up 8403.75% from -$9.1 million recorded in Q2 2025.
  • In the past 5 years, TransMedics' Cash from Investing Activities ranged from a high of $24.7 million in Q3 2022 and a low of -$149.8 million during Q3 2023
  • Over the past 5 years, TransMedics' median Cash from Investing Activities value was -$2.8 million (recorded in 2022), while the average stood at -$14.9 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 47873.29% in 2022, then plummeted by 466504.85% in 2024.
  • Over the past 5 years, TransMedics' Cash from Investing Activities (Quarter) stood at $10.0 million in 2021, then crashed by 127.66% to -$2.8 million in 2022, then tumbled by 1412.95% to -$41.8 million in 2023, then surged by 67.46% to -$13.6 million in 2024, then soared by 43.97% to -$7.6 million in 2025.
  • Its Cash from Investing Activities was -$7.6 million in Q3 2025, compared to -$9.1 million in Q2 2025 and -$27.0 million in Q1 2025.